ADC Therapeutics $60 million private placement
We advised ADC Therapeutics on the transaction involving its common shares and pre-funded warrants
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Vistra $2 billion secured notes offering
The investment-grade notes are due 2028, 2030 and 2035
TopBuild $750 million notes offering
The high-yield notes are due 2034
K. Hovnanian Enterprises $900 million high-yield senior notes offering
The high-yield notes are due 2031 and 2033
Royalty Pharma $2 billion senior notes offering
We advised Royalty Pharma on its investment-grade notes offering
AeroVironment $1.6 billion stock and convertible notes offerings
The concurrent offerings were registered with the SEC
ADC Therapeutics $100 million private placement
We advised ADC Therapeutics on the equity offering
Circle $1.05 billion IPO
We are advising Circle on its IPO, the first IPO by a stablecoin issuer
QXO $1.495 billion common and depositary share offerings
The common stock is listed on the NYSE
QXO $2.25 billion senior secured notes offering
The debut high-yield notes are part of the financing for QXO’s acquisition of Beacon Roofing Supply